A Meta-Analysis of the Association between DNMT1 Polymorphisms and Cancer Risk

Table 3

Meta-analysis results of the association between DNMT1 rs2228611 (G/A) polymorphism and cancer risk.

Genetic model	Group/subgroup	Studies	Heterogeneity test		Statistical model	Test for overall effect
			(%)			OR (95% CI)
AA versus GG	Overall	11	0.00	0.925	F	0.99 (0.84–1.19)	0.898
	Gastric cancer	3	0.00	0.774	F	0.74 (0.49–1.13)	0.165
	Breast cancer	4	0.00	0.979	F	0.98 (0.78–1.22)	0.848
	PCR–RFLP	4	0.00	0.880	F	1.04 (0.76–1.42)	0.803
	MALDI-TOF	3	0.00	0.511	F	0.87 (0.65–1.17)	0.360
GA versus GG	Overall	11	41.00	0.075	R	1.05 (0.92–1.21)	0.445
	Gastric cancer	3	0.00	0.461	F	1.07 (0.86–1.33)	0.522
	Breast cancer	4	35.60	0.198	F	1.17 (1.03–1.33)	0.016
	PCR–RFLP	4	64.00	0.040	R	1.05 (0.73–1.52)	0.782
	MALDI-TOF	3	0.00	0.910	F	1.20 (1.03–1.41)	0.022
(GA + AA) versus GG	Overall	11	1.80	0.425	F	1.05 (0.96–1.15)	0.284
	Gastric cancer	3	0.00	0.618	F	1.02 (0.83–1.26)	0.860
	Breast cancer	4	1.50	0.385	F	1.13 (1.00–1.28)	0.043
	PCR–RFLP	4	51.70	0.102	F	1.06 (0.87–1.29)	0.542
	MALDI-TOF	3	0.00	0.872	F	1.14 (0.98–1.33)	0.087
AA versus (GA + GG)	Overall	11	0.00	0.596	F	0.97 (0.83–1.13)	0.671
	Gastric cancer	3	0.00	0.535	F	0.76 (0.51–1.12)	0.169
	Breast cancer	4	0.00	0.813	F	0.90 (0.73–1.12)	0.351
	PCR–RFLP	4	0.00	0.779	F	0.99 (0.76–1.29)	0.933
	MALDI-TOF	3	0.00	0.501	F	0.80 (0.60–1.06)	0.126
A allele versus G allele	Overall	11	0.00	0.978	F	1.02 (0.95–1.10)	0.532
	Gastric cancer	3	0.00	0.863	F	0.96 (0.82–1.14)	0.660
	Breast cancer	4	0.00	0.861	F	1.06 (0.96–1.16)	0.249
	PCR–RFLP	4	0.00	0.530	F	1.03 (0.90–1.18)	0.696
	MALDI-TOF	3	0.00	0.745	F	1.04 (0.93–1.17)	0.494

R: random effect model; F: fixed effect model.